BRAIN CANCER

Latest News

Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma
Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma

April 17th 2025

Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.

FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma
FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma

April 3rd 2025

VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma
VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma

March 27th 2025

Sonodynamic Therapy Shows Promise for Glioblastoma Treatment
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment

February 25th 2025

FDA Gives Dordaviprone Priority Review in H3K27M-Mutant Diffuse Glioma
FDA Gives Dordaviprone Priority Review in H3K27M-Mutant Diffuse Glioma

February 19th 2025

More News